Translational Research Program 2027

The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness.

For the 2027 grant cycle, TRP applications must demonstrate translational readiness. The following criteria apply:

• Small molecule therapies: Applications must include in vivo proof of concept (POC) in appropriate animal models. In select cases, strong in vitro POC using patient-derived samples may be considered, depending on the mechanism of action.
• Cellular and immunotherapies: In vivo POC is strongly encouraged. However, in vitro POC may be acceptable where it is most appropriate for the therapeutic approach.

Funding: $250,000 per year ($750,000 total) 
Duration: 3 years

Research Authority due date: 8.10.26
LOI (required) due date: 16.10.26
Full proposal due date: 22.1.27